Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms
EHA Learning Center, Maria T Georgescu, 226762
The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation
EHA Learning Center, Alessandra Roberto, 226761
Meaningful changes in end-of-life care among patients with myeloma
EHA Learning Center, Oreofe O. Odejide, 226760
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
EHA Learning Center, Jingsong He, 226759
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
EHA Learning Center, Joséphine Muller, 226758
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
EHA Learning Center, Marek Trneny, 226757
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi
EHA Learning Center, Sergio Storti, 226756
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
EHA Learning Center, Christopher Melani, 226755
Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites
EHA Learning Center, Sarah Moody, 226754
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
EHA Learning Center, Dalila Salvatore, 226753
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
EHA Learning Center, Gail Roboz, 226752
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
EHA Learning Center, Carlo Gambacorti-Passerini, 226751
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
EHA Learning Center, Rajeswaran Mani, 226750
Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients
EHA Learning Center, Jean Donadieu, 226749
CARD10, a CEBPE target involved in granulocytic differentiation
EHA Learning Center, Pavithra Shyamsunder, 226748
A Paradigm Shift: Emerging Therapies in Flt3-Positive AML
EHA Learning Center, Delivered by Novartis, 224083
Setd2 regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation
EHA Learning Center, Yle Zhou, 224103
Endothelin type A receptors mediate pain in a mouse model of sickle cell disease
EHA Learning Center, Brianna Marie Lutz, 224104
Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction
EHA Learning Center, Sanjay Tewari, 224105
Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience
EHA Learning Center, Ilhem Rahal, 224106
Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes
EHA Learning Center, Valentina Giudice, 224107
JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury
EHA Learning Center, Chi Hua Sarah Lin, 224108
The chromatin-remodeling factor CHD4 is required for maintenance of childhood acute myeloid leukemia
EHA Learning Center, Yaser Heshmati, 224109
Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2
EHA Learning Center, Heike Horn, 224110
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
EHA Learning Center, Monica Bellei, 224111
Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome
EHA Learning Center, Ignacio Criado, 224112
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
EHA Learning Center, Antonio Cuneo, 224113
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment
EHA Learning Center, Christine Lam, 224114
Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation
EHA Learning Center, M. Hasib Sidiqi, 224115
Platelet Munc13-4 regulates hemostasis, thrombosis and airway inflammation
EHA Learning Center, Eduardo I. Cardenas, 224116
C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study
EHA Learning Center, Gro Grimnes, 224117
Macrocytic anaemia with thrombocytosis
EHA Learning Center, Jaroslav Cermak, 221464
Expert interview with Wilma Barcellini
EHA Learning Center, Wilma Barcellini, 226242
Expert interview with Eleni Gavriilaki
EHA Learning Center, Eleni Gavriilaki, 226241
Expert interview with Jacqueline Boultwood
EHA Learning Center, Jacqueline Boultwood, 226240
Expert interview with Adam Mead
EHA Learning Center, Adam Mead, 226239
Expert interview with Jacob Odeberg
EHA Learning Center, Jacob Odeberg, 226238
Expert interview with Valentine Brousse
EHA Learning Center, Valentine Brousse, 226237
Expert interview with Norbert Gattermann
EHA Learning Center, Norbert Gattermann, 226236
Expert interview with Francesco Lo Coco
EHA Learning Center, Francesco Lo Coco, 226235
Expert interview with Francesco d'Amore
EHA Learning Center, F D'Amore, 226234
Expert interview with Tsvee Lapidot
EHA Learning Center, Tsvee Lapidot, 221461
Cancer and Trombosis: can we predict it?
EHA Learning Center, Nick van Es, 221460
Listen to the patient
EHA Learning Center, Fabio Efficace, 221459
What's new in CLL?
EHA Learning Center, Michael Hallek, 221458
Expert interview with Carl June
EHA Learning Center, Carl June, 221457
Expert interview with Marion Subklewe
EHA Learning Center, Marion Subklewe, 225610
Expert interview with Sara Gorashian
EHA Learning Center, Sara Gorashian, 225609
Expert interview with Jyoti Nangalia
EHA Learning Center, Jyoti Nangalia, 225608
Amyloidosis: The rapidly changing face of diagnosis and therapy in AL amyloidosis
EHA Learning Center, Giampaolo Merlini, 219242
Treating Thalassemia: Thinking 'out of the box'
EHA Learning Center, Stefano Rivella, 219243
Normal and leukemic hematopoiesis in the bone marrow. Metabolic regulation in a dynamic environment
EHA Learning Center, Tsvee Lapidot, 219244
ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY
EHA Learning Center, Meletios A Dimopoulos, 218888
CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Steffen Boettcher, 218887
THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB
EHA Learning Center, Rocco Piazza, 218886
RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS
EHA Learning Center, Jong Wook Lee, 218885
From epidemiology to treatment decisions (the role of T cell registries)
EHA Learning Center, Massimo Federico, 219234
PTCL: Evidence for subtype specific treatment approaches?
EHA Learning Center, F D'Amore, 219235
NK/T cell lymphoma: Novel insights, novel therapies?
EHA Learning Center, Won Seog Kim, 219236
HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY
EHA Learning Center, Lydia Scarfo, 218883
HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY
EHA Learning Center, Lydia Scarfo, 219219
MAPPING THE THREE-DIMENSIONAL GENOME DYNAMICS IN NORMAL AND NEOPLASTIC B CELLS
EHA Learning Center, Iñaki Martin-Subero, 219220
RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS
EHA Learning Center, Jong Wook Lee, 219221
THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB
EHA Learning Center, Rocco Piazza, 219222
CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Steffen Boettcher, 219223
ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY
EHA Learning Center, Meletios A Dimopoulos, 219224
Mechanisms underlying oncogenic transcription factors in ALL
EHA Learning Center, Jan Cools, 219226
Novel genetic subgroups in acute lymphoblastic leukemia
EHA Learning Center, Christine Harrison, 219227
Current concepts in ALL frontline trials in children and young adults
EHA Learning Center, Mats Heyman, 219228
Single cell genomics in CML
EHA Learning Center, Adam Mead, 219230
Immune targeting of CML to improve treatment outcome
EHA Learning Center, Andreas Burchert, 219231
TFR treatment goal for all CML patients
EHA Learning Center, Delphine Rea, 219232
Future prospects for the treatment of hemophilia: A global perspective
EHA Learning Center, David Lillicrap, 219238
Monoclonal antibody-based therapies
EHA Learning Center, Midori Shima, 219239
Modified FVIII and FIX recombinant products
EHA Learning Center, Elena Santagostino, 219240
Treating thalassemia with iron restriction
EHA Learning Center, Stefano Rivella, 223400
Is getting old bad?
EHA Learning Center, Michael Heuser, 223399
CAR -T cell therapy: Here to say?
EHA Learning Center, Peter Borchmann, 223398
The best treatment for SAA?
EHA Learning Center, Jakob R Passweg, 223397
Anemia in the elderly: is it real?
EHA Learning Center, Domenico Girelli, 223396
Iron Metabolism: what do you need to know?
EHA Learning Center, Tomas Ganz, 223395
Marginal Zone Lymphona: from diagnosis to treatment
EHA Learning Center, Catherine Thieblemont, 223394
Microenvironment in MPN
EHA Learning Center, Simon Mendez-Ferrer, 219198
Inflammation and anti-inflammatory approaches in MPN
EHA Learning Center, Steffen Koschmieder, 219199
Stem cell transplantation for myelofibrosis
EHA Learning Center, Nicolaus Kröger, 219200
Which are the preferred treatment combinations and sequence(s): In the transplant eligible / In the elderly
EHA Learning Center, Hartmut Goldschmidt, 219201
What are the treatment goals and optimal endpoints in RRMM
EHA Learning Center, Thierry Facon, 219202
How I manage extramedullary disease and plasma cell leukemia
EHA Learning Center, María-Victoria Mateos, 219203
Biology of secondary leukemia
EHA Learning Center, Timothy Graubert, 219205
Impact of underlying disease on secondary leukemia
EHA Learning Center, Lene Sofie Granfeldt Østgård, 219206
Prognostic factors and treatment options in secondary leukemia
EHA Learning Center, Maria Teresa Voso, 219207
Precision hematology: Implementing genomic profiling at national level
EHA Learning Center, Richard Rosenquist, 219209
Towards a molecular classification of Philadelphia- negative myeloproliferative neoplasms
EHA Learning Center, Radek Skoda, 219210
Molecular characterization as a basis for novel treatment paradigms in AML
EHA Learning Center, Hartmut Döhner, 219211
Assessing MRD in multiple myeloma
EHA Learning Center, Hervé Avet-Loiseau, 219212
New immunomodulators - New infectious diseases mind set?
EHA Learning Center, Sibylle Mellinghoff, 219214
Aspergillus resistance: Time to change the antifungal approach?
EHA Learning Center, Katrien Lagrou, 219215
One size does not fit all: Improving outcomes with personalized infection management?
EHA Learning Center, Martin Hönigl, 219216
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIC PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
EHA Learning Center, Esther Natalie Oliva, 214478
OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PRIOR BLINATUMOMAB IN ZUMA-3, A STUDY OF KTE-C19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
EHA Learning Center, Olalekan O. Oluwole, 214484

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings